reading the new retatrutide paper, but with my side-effect hat on

2026-10-07 1262 views 2 posts

2026-10-07 05:47

I read the full TRIUMPH-1 paper over coffee this morning, mostly because I wanted the actual adverse-event tables and not just the headline number. The triple-agonist mechanism is fascinating, and in the trials the weight-loss signal looks strong.

But what I keep thinking about is tolerability: a drug can look great on average and still be a rough ride for the people who drop out early. I'm 11 months on tirzepatide, down 29 lbs, and my main win has been quieter food noise rather than a dramatic scale plunge.

So I'm curious whether folks here care more about the average loss or the dropout/side-effect details when a new paper drops?

2026-10-13 14:08

I was glad you mentioned the adverse-event tables. One thing I look for is whether nausea or fatigue was reported as intermittent or persistent, because a weekly average can smooth over two rough days.

I track a simple 1–10 comfort score alongside my weekly weight average, plus protein and fluids, and that pattern is often more useful than the scale alone. Did the paper break side effects out by week, or only pool them across the trial?

That distinction would really change how I read tolerability.

Back to Tirzepatide (Mounjaro, Zepbound)